In principle yes.
Yes, subcontracting of clinical studies is possible.
Clinical trials can be subcontracted.
Then it is not research infrastructure, but deployment infrastructure that should be checked in your specific case by your health NCP and SME-NCP.
Out-licensing after Phase 2 can be considered as market uptake.
Unfortunately not. Actions should focus on bringing a product or service to the market.
There is no exclusion of medical devices.
That is a risk you should address in your application.
It is surely a decision criterium with equal points among several applications.
Austrian Research Promotion Agency